KLK3 and prostate carcinoma: However, USPSTF on review of the most recent evidence, recently recommended against prostate-specific antigen-based screening for prostate cancer (grade D recommendation: there is moderate or high certainty that screening has no net benefit) for all men in the general US population, regardless of age [208].